Product Reports Resources Pricing Login Book a demo

BioNano Genomics

Biotech & Life Sciences · San Diego, United States · Founded 2003 · IPO 2018

Next-generation genome mapping and analysis tools help researchers see true genome structure to fill in what’s missing from sequencing-based data

Valuation $15M
Revenue $32M
Power Law Colt$25–100M revenue

Talent graph

BioNano Genomics's talent

Book a demo to see the people
Employees mapped 174 incl. 3 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 29 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

12 investors on BioNano Genomics's cap table

Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.

Seed 2 investors entered at this stage
Ben Franklin Technology Partners of Southeastern Pennsylvania
21Ventures
Series A 2 investors entered at this stage
Battelle Ventures
KT Venture Group
Series B+ 8 investors entered at this stage
Gund Investment
Newzone Venture Capital
Princeton University
Domain Associates
Legend Capital
Monashee Capital Corp.
Novartis Venture Fund
Federated Hermes

Global footprint

Where BioNano Genomics has talent and traffic

Workforce by country
🇺🇸 United States · San Diego HQ
Book a demo for the full country breakdown
Web traffic by country
15K monthly visits
across markets
🇺🇸 United States38.7%
🇨🇦 Canada18.7%
🇬🇧 United Kingdom12.7%
🇮🇳 India9.3%
🇪🇸 Spain8.7%
Top 5 markets shown

Capital deployed

BioNano Genomics's 3 investments and acquisitions.

Every disclosed deal where BioNano Genomics appeared as a backer or acquirer, 2020–2022. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

3 deals across BioNano Genomics's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        02 · Portfolio market map

        BioNano Genomics's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        3 of 3 deals

        Market sentiment

        What the market is saying about BioNano Genomics

        An AI-synthesized read of the highest-engagement posts about BioNano Genomics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See BioNano Genomics on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

        Book a demo Explore company profiles